Prulifloxacin
From Wikipedia, the free encyclopedia
| Please help improve this article or section by expanding it. Further information might be found on the talk page or at requests for expansion. (March 2008) |
|
Prulifloxacin
|
|
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | ? |
| ATC code | J01 |
| PubChem | |
| Chemical data | |
| Formula | C21H20FN3O6S |
| Mol. mass | 461.463403 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | By esterases, to ulifloxacin |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Prulifloxacin (INN) is a broad-spectrum fluoroquinolone antibiotic. It is a prodrug, and is metabolized in the body to the active compound ulifloxacin. Prulifloxacin has a long half-life and may therefore be taken only once a day.[1]
In clinical trials, prulifloxacin appeared as effective as ciprofloxacin, co-amoxiclav or pefloxacin in the treatment of bronchitis exacerbations or lower urinary tract infections. It was tolerated as well as ciprofloxacin.[1]
[edit] References
- ^ a b Keam SJ, Perry CM (2004). "Prulifloxacin". Drugs 64 (19): 2221–34; discussion 2235–6. PMID 15456336.
|
|||||||||||

